Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Chugai Sues 4 Companies Including Iwaki Seiyaku for Patent Infringement Related to Oxarol Ointment
February 21, 2013
- HIV Treatment Dolutegravir Gets FDA Priority Review: ViiV Healthcare
February 21, 2013
- Radium-223 Granted Priority Review Status by US FDA: Bayer HealthCare
February 19, 2013
- DSP Targets Sales of 450 Billion Yen in FY2017 by Making Latuda Blockbuster
February 19, 2013
- Blopress Retakes Top Spot in Domestic Ethical Drug Market in 2012: IMS Japan
February 19, 2013
- Kowa Says Listing Application for Livalo Generic “Won’t Be Filed”; Possibility Nixed for 1st AG in Japan
February 18, 2013
- No Statistical Significance Shown in OS between Tivozanib and Sorafenib in PIII Study: Astellas
February 18, 2013
- Nihon Medi-Physics to Establish New Manufacturing Base for PET Diagnostics in Fujioka City, Gunma Prefecture
February 18, 2013
- Small and Medium Sized Pharmacies Jointly Buys Generics Directly from Manufacturers
February 15, 2013
- Takeda Subsidiary Suspends Operations for 12 Days Due to Alinamin-F5 Injection Recalls
February 15, 2013
- Daiichi Sankyo to Launch New Firm for Duchenne Muscular Dystrophy Therapy Jointly with Govt-Backed Fund
February 15, 2013
- Nichi-Iko to Open Representative Office in Thailand on April 1
February 14, 2013
- AZ Takes Over GLP-1 Receptor Agonist Bydureon from Eli Lilly in Japan
February 14, 2013
- Allegra, Allelock Face Stiff Competition from Generics in Anti-Allergic Drug Market
February 14, 2013
- Otsuka Holdings Pharmaceutical Sales Up 3.4% in April-December Thanks to Abilify Sales Hike
February 14, 2013
- Samsca 7.5 mg Tablets Approved: Otsuka
February 14, 2013
- Novartis Will Explain to Doctors that 2009 Article on Diovan Is Invalid: President Mitani
February 13, 2013
- Bristol-Myers, Pfizer Underline Eliquis’s Superiority vs. Warfarin
February 13, 2013
- Novartis Sales Up 2.5% in 2012 Thanks to Rapid Growth in New Fields
February 13, 2013
- Sales of 10 Top European, US Drug Makers See Sharp Declines in 2012 Due to Patent Cliff
February 13, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…